Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Bullish on Akamai Technologies Raises Price Target to 140

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
Technology Blockchain Stock Market Today
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Tigress Financial analyst Ivan Feinseth is bullish on Akamai Technologies (NASDAQ: AKAM), maintaining a Strong Buy rating and increasing the price target to $140. Akamai’s recent performance, including a 23% EPS growth and 7% sales growth last quarter, supports this positive outlook. The company’s strong financial health, with an interest coverage ratio of 81.68 and a Debt-to-Revenue ratio of 0.9, further reinforces its potential. Analysts believe Akamai Technologies may be undervalued, with a fair value estimate of $158 based on Free Cash Flow to Equity analysis. With its financial strength, profitability, and growth metrics, Akamai Technologies is poised for potential outperformance, presenting an attractive investment opportunity.

AKAM Stock Price Drops Slightly on March 8, 2024: Potential for Future Growth

On March 8, 2024, Akamai Technologies, Inc. (AKAM) experienced a slight decrease in its stock price, with shares dropping by $2.09, or 1.85%, since the market last closed. The stock opened at $112.62, which was $0.21 lower than its previous close.

Despite the drop in price on that particular day, AKAM has been performing well overall, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been experiencing positive momentum and may have the potential for further growth in the future.

Investors should keep an eye on AKAM’s stock performance in the coming days to see if the slight drop on March 8 was just a temporary dip or if it is indicative of a larger trend. It is always important to consider a variety of factors, such as market conditions, company news, and industry trends, when making investment decisions.

AKAM Stock Performance Analysis: Positive Yearly Growth, Flat Quarter Comparison

On March 8, 2024, AKAM stock had a mixed performance based on the financial data provided by CNN Money. The company reported a total revenue of $3.81 billion for the past year, which was a 5.4% increase compared to the previous year. However, the total revenue for the fourth quarter was $995.02 million, holding flat compared to the previous quarter.

Similarly, AKAM reported a net income of $547.63 million for the past year, reflecting a 4.57% increase compared to the previous year. The net income for the fourth quarter was $161.16 million, holding flat compared to the previous quarter.

Earnings per share (EPS) for AKAM were $3.52 for the past year, showing a 7.99% increase compared to the previous year. The EPS for the fourth quarter was $1.03, holding flat compared to the previous quarter.

Overall, AKAM’s financial performance on March 8, 2024, showed a positive trend in terms of total revenue, net income, and earnings per share compared to the previous year. However, the company’s performance held flat since the previous quarter, indicating a stable but not necessarily growing trend in the short term.

Investors and analysts may want to closely monitor AKAM’s future financial reports to assess whether the company can maintain or improve its financial performance in the coming quarters. Market conditions, industry trends, and company-specific factors could all impact AKAM’s stock performance in the future.

Tags: AKAM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Commercial (2)

Whales Show Positive Outlook on Walmart Stock Options

Retail Stock Bull Market

Analyst Insights Victorias Secret Ratings and Price Targets as of March 8 2024

Technology Quantum computing Stock Exchange

Analyst Reiterates Positive Outlook on Samsara with Increased Price Target

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com